Pharma/Device Combination Product Incentives Under Consideration At FDA
This article was originally published in The Pink Sheet Daily
User fee reductions or waivers and exclusivity incentives are tools at FDA’s disposal to make cooperating with device firms more attractive to pharmaceutical manufacturers. Such incentives may still be insufficient to draw pharma manufacturers’ interest, an agency attorney says.
You may also be interested in...
Although drug companies can be reluctant to partner with device firms on combo products, it is not FDA’s role to coerce firms to partner on cross-labeling development, participants at a Regulatory Affairs Professionals Society summit say. FDA will hold a meeting on cross-labeling in the spring.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products